LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Prevalence of feral swine disturbance at important archaeological sites over a large landscape in Florida.

    Engeman, Richard M / Meyer, Joseph S / Allen, John B

    Scientific reports

    2017  Volume 7, Page(s) 40287

    Abstract: Feral swine are globally known as one of the most destructive invasive vertebrates, damaging native habitats, native plants and animals, agriculture, infrastructure, spreading diseases. There has been little quantification on their disturbance to ... ...

    Abstract Feral swine are globally known as one of the most destructive invasive vertebrates, damaging native habitats, native plants and animals, agriculture, infrastructure, spreading diseases. There has been little quantification on their disturbance to archaeological sites across a broad landscape. Over 6 years we inspected 293 significant archaeological sites for swine disturbance across a vast area. We found a 42% prevalence of swine disturbance among all sites, with prevalence not distinguishable among prehistoric sites, historic sites, and sites with both components. The areas of disturbance mapped within three historic homestead sites showed 5-26% of total site surface area rooted. Disturbance was not evident upon re-inspection of one of these sites after 18 months, indicating how evidence of disturbance can be obscured in this environment. Thus, our observed 42% prevalence of disturbance should be considered a minimum for disturbance occurring through time. Artifacts depths were <10 cm of the surface at 85% of the sites and <20 cm of the surface for 90% of the sites. Feral swine rooting commonly exceeds 20 cm in depth, especially in soft sandy substrates typical of Florida, making the great majority of the studied sites highly vulnerable to artifact damage or displacement.
    Language English
    Publishing date 2017--10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/srep40287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes.

    Martinez, Christine E / Allen, John B / Davidorf, Frederick H / Cebulla, Colleen M

    BMJ case reports

    2017  Volume 2017

    Abstract: A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with ... ...

    Abstract A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Bacteremia/complications ; Bacteremia/microbiology ; Diabetes Complications ; Diabetes Mellitus, Type 2/complications ; Endophthalmitis/drug therapy ; Endophthalmitis/etiology ; Endophthalmitis/microbiology ; Eye/pathology ; Eye Infections, Bacterial/complications ; Eye Infections, Bacterial/microbiology ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Interleukin-17/antagonists & inhibitors ; Male ; Methicillin-Resistant Staphylococcus aureus ; Middle Aged ; Osteomyelitis/drug therapy ; Osteomyelitis/etiology ; Osteomyelitis/microbiology ; Pain/etiology ; Psoriasis/drug therapy ; Staphylococcal Infections/complications ; Staphylococcal Infections/microbiology ; Vision, Low/etiology
    Chemical Substances Anti-Bacterial Agents ; Antibodies, Monoclonal ; Immunologic Factors ; Interleukin-17 ; secukinumab (DLG4EML025)
    Language English
    Publishing date 2017-06-29
    Publishing country England
    Document type Case Reports ; Journal Article
    ISSN 1757-790X
    ISSN (online) 1757-790X
    DOI 10.1136/bcr-2017-219296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Effects of incision location on specimen quality and complications for temporal artery biopsy.

    Czyz, Craig N / Allen, John B / Cahill, Kenneth V / Nabavi, Cameron B / Foster, Jill A

    Vascular

    2018  Volume 27, Issue 4, Page(s) 347–351

    MeSH term(s) Aged ; Aged, 80 and over ; Biopsy/adverse effects ; Biopsy/methods ; Biopsy/standards ; Facial Nerve Injuries/etiology ; Female ; Giant Cell Arteritis/pathology ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Temporal Arteries/pathology
    Language English
    Publishing date 2018-12-05
    Publishing country England
    Document type Comparative Study ; Journal Article
    ZDB-ID 2137151-9
    ISSN 1708-539X ; 1708-5381
    ISSN (online) 1708-539X
    ISSN 1708-5381
    DOI 10.1177/1708538118818618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.

    Jhaveri, Chirag D / Glassman, Adam R / Ferris, Frederick L / Liu, Danni / Maguire, Maureen G / Allen, John B / Baker, Carl W / Browning, David / Cunningham, Matthew A / Friedman, Scott M / Jampol, Lee M / Marcus, Dennis M / Martin, Daniel F / Preston, Carin M / Stockdale, Cynthia R / Sun, Jennifer K

    The New England journal of medicine

    2022  Volume 387, Issue 8, Page(s) 692–703

    Abstract: Background: In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) ... ...

    Abstract Background: In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear.
    Methods: At 54 clinical sites, we randomly assigned eyes in adults who had diabetic macular edema involving the macular center and a visual-acuity letter score of 24 to 69 (on a scale from 0 to 100, with higher scores indicating better visual acuity; Snellen equivalent, 20/320 to 20/50) to receive either 2.0 mg of intravitreous aflibercept or 1.25 mg of intravitreous bevacizumab. The drug was administered at randomization and thereafter according to the prespecified retreatment protocol. Beginning at 12 weeks, eyes in the bevacizumab-first group were switched to aflibercept therapy if protocol-specified criteria were met. The primary outcome was the mean change in visual acuity over the 2-year trial period. Retinal central subfield thickness and visual acuity at 2 years and safety were also assessed.
    Results: A total of 312 eyes (in 270 adults) underwent randomization; 158 eyes were assigned to receive aflibercept monotherapy and 154 to receive bevacizumab first. Over the 2-year period, 70% of the eyes in the bevacizumab-first group were switched to aflibercept therapy. The mean improvement in visual acuity was 15.0 letters in the aflibercept-monotherapy group and 14.0 letters in the bevacizumab-first group (adjusted difference, 0.8 letters; 95% confidence interval, -0.9 to 2.5; P = 0.37). At 2 years, the mean changes in visual acuity and retinal central subfield thickness were similar in the two groups. Serious adverse events (in 52% of the patients in the aflibercept-monotherapy group and in 36% of those in the bevacizumab-first group) and hospitalizations for adverse events (in 48% and 32%, respectively) were more common in the aflibercept-monotherapy group.
    Conclusions: In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we found no evidence of a significant difference in visual outcomes over a 2-year period between aflibercept monotherapy and treatment with bevacizumab first with a switch to aflibercept in the case of suboptimal response. (Funded by the National Institutes of Health; Protocol AC ClinicalTrials.gov number, NCT03321513.).
    MeSH term(s) Adult ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Diabetes Mellitus/drug therapy ; Diabetic Retinopathy/complications ; Diabetic Retinopathy/drug therapy ; Humans ; Intravitreal Injections ; Macular Edema/drug therapy ; Macular Edema/etiology ; Ranibizumab/adverse effects ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/therapeutic use ; Vascular Endothelial Growth Factor A
    Chemical Substances Angiogenesis Inhibitors ; Recombinant Fusion Proteins ; Vascular Endothelial Growth Factor A ; aflibercept (15C2VL427D) ; Bevacizumab (2S9ZZM9Q9V) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Ranibizumab (ZL1R02VT79)
    Language English
    Publishing date 2022-07-14
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2204225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania.

    Parks, Tom / Mirabel, Mariana M / Kado, Joseph / Auckland, Kathryn / Nowak, Jaroslaw / Rautanen, Anna / Mentzer, Alexander J / Marijon, Eloi / Jouven, Xavier / Perman, Mai Ling / Cua, Tuliana / Kauwe, John K / Allen, John B / Taylor, Henry / Robson, Kathryn J / Deane, Charlotte M / Steer, Andrew C / Hill, Adrian V S

    Nature communications

    2017  Volume 8, Page(s) 14946

    Abstract: The indigenous populations of the South Pacific experience a high burden of rheumatic heart disease (RHD). Here we report a genome-wide association study (GWAS) of RHD susceptibility in 2,852 individuals recruited in eight Oceanian countries. Stratifying ...

    Abstract The indigenous populations of the South Pacific experience a high burden of rheumatic heart disease (RHD). Here we report a genome-wide association study (GWAS) of RHD susceptibility in 2,852 individuals recruited in eight Oceanian countries. Stratifying by ancestry, we analysed genotyped and imputed variants in Melanesians (607 cases and 1,229 controls) before follow-up of suggestive loci in three further ancestral groups: Polynesians, South Asians and Mixed or other populations (totalling 399 cases and 617 controls). We identify a novel susceptibility signal in the immunoglobulin heavy chain (IGH) locus centring on a haplotype of nonsynonymous variants in the IGHV4-61 gene segment corresponding to the IGHV4-61*02 allele. We show each copy of IGHV4-61*02 is associated with a 1.4-fold increase in the risk of RHD (odds ratio 1.43, 95% confidence intervals 1.27-1.61, P=4.1 × 10
    MeSH term(s) Adult ; Alleles ; Asians ; Case-Control Studies ; Child ; Female ; Gene Expression ; Genetic Predisposition to Disease ; Genome-Wide Association Study ; Haplotypes ; Humans ; Immunoglobulin Heavy Chains/genetics ; Immunoglobulin Heavy Chains/immunology ; Male ; Native Hawaiian or Other Pacific Islander ; Oceania ; Odds Ratio ; Rheumatic Heart Disease/ethnology ; Rheumatic Heart Disease/genetics ; Rheumatic Heart Disease/immunology ; Rheumatic Heart Disease/pathology ; Risk
    Chemical Substances Immunoglobulin Heavy Chains
    Language English
    Publishing date 2017-05-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/ncomms14946
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: MIF promoter polymorphisms are associated with epiretinal membrane but not retinal detachment with PVR in an american population.

    Cebulla, Colleen M / Stevenson, William / Van Law, Heather / Heisler-Taylor, Tyler / Hamadmad, Sumaya / Shah, Mohd Hussain / Kim, Bongsu / Davidorf, Frederick H / Ohr, Matthew / Wells, Michael / Yanoga, Fatoumata / Chang, Susie / Terrell, William / Miller, Daniel M / Klisovic, Dino / Allen, John B / Shah, Niraj / Geraymovych, Elena / Tarabishy, Ahmad B /
    Kondapalli, Srinivas S / Brewington, Beatrice Y / Inman, Andrea / Williams, Demarcus / Kusibati, Rania / Mathias, Jay / Vedat, Yildiz / Fernandez, Soledad / Wisely, C Ellis / Pilarski, Robert / Abdel-Rahman, Mohamed H

    Experimental eye research

    2019  Volume 185, Page(s) 107667

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Epiretinal Membrane/genetics ; Epiretinal Membrane/pathology ; Female ; Genotyping Techniques ; Humans ; Intramolecular Oxidoreductases/genetics ; Macrophage Migration-Inhibitory Factors/genetics ; Male ; Middle Aged ; Polymerase Chain Reaction ; Polymorphism, Single Nucleotide/genetics ; Promoter Regions, Genetic/genetics ; Retinal Detachment/genetics ; Retinal Detachment/pathology ; United States ; Vitreoretinopathy, Proliferative/genetics ; Vitreoretinopathy, Proliferative/pathology ; Young Adult
    Chemical Substances Macrophage Migration-Inhibitory Factors ; Intramolecular Oxidoreductases (EC 5.3.-) ; MIF protein, human (EC 5.3.2.1)
    Language English
    Publishing date 2019-05-17
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80122-7
    ISSN 1096-0007 ; 0014-4835
    ISSN (online) 1096-0007
    ISSN 0014-4835
    DOI 10.1016/j.exer.2019.05.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top